Discovery of the anti-influenza A virus activity of SB216763 and cyclosporine A by mining infected cells and compound cellular signatures  

作　　者：Ke Tang You Wu Shubing Chen Yijing Xin Ying Guo 

机构地区：[1]State Key Laboratory of Bioactive Substance and Function of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China [2]Department of Pharmacology,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China

出　　处：《Chinese Chemical Letters》2022年第5期2541-2544,共4页中国化学快报（英文版）

基　　金：supported by the CAMS Innovation Fund for Medical Sciences (Nos. 2021-I2M-1-028 and 2020I2M-2-010);the Opening Foundation of the State Key Laboratory of Bioactive Substance and Function of Natural Medicines (No. GTZK202109);the National Natural Science Foundation of China (No. 81473256);the Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study (No. BZ0150);the Disciplines Construction Project (No. 201920200802)

摘　　要：In this study,SB216763 and cyclosporine A were identified as anti-influenza A virus(IAV)agents by tran-scriptome signature reversion(TSR)analysis through deep mining of the cellular transcriptome of hu-man airway and lung cell lines infected with 3 strains of IAV and the chemical perturbations library.A synergistic effect of SB216763 and cyclosporine A against influenza A was disclosed by quantification of the network-based relationship,which was validated in vitro.Along with burgeoning omics approaches,transcriptome-based drug development is flourishing,which provides a novel insight into antivirals dis-covery with comprehensive cellular transcriptional information of disease and chemical perturbations in multicomponent intervention.This strategy can be applied as a new approach in discovering multitar-get antiviral agents from approved drugs,clinical compounds,natural products or other known bioactive compounds.

关 键 词：Chemical perturbagen signature Host factor Transcriptome signature reversion Influenza A virus SB216763 Cyclosporine A Drug combination 

分 类 号：R96[医药卫生—药理学] TQ460.1[医药卫生—药学]